PAREXEL EXPERTS TO ADDRESS STRATEGIC PARTNERING BEST PRACTICES AND GLOBAL TRIAL REQUIREMENTS AT PARTNERSHIPS IN CLINICAL TRIALS CONFERENCE
Boston, MA, April 7, 2010—Experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will present key industry topics during the 19th Annual Partnerships in Clinical Trials Conference, to be held April 12-14, 2010 in Orlando, Florida. Thought leaders from PAREXEL, a sponsor of the conference, will discuss best practices in strategic partnering as well as requirements for global clinical trials.
PAREXEL experts will also be available during the meeting to address other key industry issues. PAREXEL will provide a number of complimentary advisories and white papers to biopharmaceutical companies visiting PAREXEL’s Booth #313 in the exhibit hall. The materials include a handbook addressing country-by-country insights into the key challenges and opportunities for development in the Asia/Pacific region.
Attendees can visit experts from Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL, at Booths #413 and #415 to view demonstrations of Perceptive’s eClinical Suite, featuring convergence between its DataLabs® Electronic Data Capture (EDC) system and ClinPhone® RTSM (Randomization and Trial Supply Management) solutions. Focused on improving trial efficiency and streamlining workflow, the eClinical Suite supports real-time data interchange and enables diverse applications to work synergistically.
The conference program features a panel session including Graciela Racaro, Senior Director, Global Research Operations, Clinical Research Services, PAREXEL who will present “Clinical Trial Requirements: Similarities and Differences from a Global Perspective—Managing and Executing a Trial to be Approvable by Regulators.” The panel session will be held on Tuesday, April 13 at 5:30 p.m. ET
As an innovator in defining partnerships in the biopharmaceutical industry for over two decades, PAREXEL utilizes a spectrum of relationship models to meet the diverse requirements of its customers. PAREXEL draws on proven processes, verifiable metrics, robust governance, mutual accountability, and a commitment to continuous improvement in developing long-term strategic relationships. To help partners accelerate completion of milestones, increase efficiency, and reduce costs, PAREXEL leverages its dedication, expertise, and innovation as well as its global reach. For information about The Expert Office at PAREXEL, a global team of experts who collaborate with customers to provide customized strategies and oversee optimal execution of trials, visit: http://www.parexel.com/ExpertOffice/index.html.
For more information about PAREXEL visit www.PAREXEL.com or Booth #313 at the Partnerships in Clinical Trials Conference. More information about the conference can be found at: http://www.iirusa.com/cropartners/welcome-to-CROs.xml.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 9,200 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings, including the anticipated restructuring charge of approximately $30 million over the second and third quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2009 as filed with the SEC on February 5, 2010, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.